Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naval Daver

Showing results (321-330 of 436) with videos related to

Pageof 44
Sort By:
The Lancet. Oncology|October 4, 2015
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 studyElias Jabbour, Hagop Kantarjian, Farhad Ravandi, et al.
Hematological Oncology|August 29, 2018
Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndromeChristopher B Benton, Kelly S Chien, Ayalew Tefferi, et al.
Nature Medicine|May 26, 2022
A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemiaAndy G X Zeng, Suraj Bansal, Liqing Jin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2015
A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic LeukemiaNaval Daver, Yanis Boumber, Hagop Kantarjian, et al.
Blood|September 19, 2025
FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AMLReeja Raj, Samanta Catueno, Amber Gibson, et al.
British Journal of Haematology|August 23, 2023
Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemiaGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Ziyi Li, et al.
Leukemia|May 9, 2025
Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangementsAlex Bataller, Hannah E Goulart, Ghayas C Issa, et al.
Cancer|October 4, 2016
Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual diseaseGhayas C Issa, Hagop M Kantarjian, C Cameron Yin, et al.
American Journal of Hematology|November 12, 2020
The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomesKoji Sasaki, Elias J Jabbour, Farhad Ravandi, et al.
Cancer|June 28, 2021
Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapySangeetha Venugopal, Mahran Shoukier, Marina Konopleva, et al.
Pageof 44

Showing results (321-330 of 436) with videos related to

Sort By:
Pageof 44
The Lancet. Oncology|October 4, 2015
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 studyElias Jabbour, Hagop Kantarjian, Farhad Ravandi, et al.
Hematological Oncology|August 29, 2018
Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndromeChristopher B Benton, Kelly S Chien, Ayalew Tefferi, et al.
Nature Medicine|May 26, 2022
A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemiaAndy G X Zeng, Suraj Bansal, Liqing Jin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2015
A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic LeukemiaNaval Daver, Yanis Boumber, Hagop Kantarjian, et al.
Blood|September 19, 2025
FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AMLReeja Raj, Samanta Catueno, Amber Gibson, et al.
British Journal of Haematology|August 23, 2023
Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemiaGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Ziyi Li, et al.
Leukemia|May 9, 2025
Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangementsAlex Bataller, Hannah E Goulart, Ghayas C Issa, et al.
Cancer|October 4, 2016
Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual diseaseGhayas C Issa, Hagop M Kantarjian, C Cameron Yin, et al.
American Journal of Hematology|November 12, 2020
The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomesKoji Sasaki, Elias J Jabbour, Farhad Ravandi, et al.
Cancer|June 28, 2021
Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapySangeetha Venugopal, Mahran Shoukier, Marina Konopleva, et al.
Pageof 44